The nootropic concept and its prospective implications

  title={The nootropic concept and its prospective implications},
  author={Corneliu E. Giurgea},
  journal={Drug Development Research},
  • C. Giurgea
  • Published 1982
  • Medicine
  • Drug Development Research
Giurgea, C.E.: The nootropic concept and its prospective implications. Drug. Dev. Res. 2:441–446, 1982. 

Klinische Bewertung der Wirksamkeit von Nootropika

Da tier- und humanexperimentell ermittelte pharmakologische und biochemische Untersuchungsergebnisse lediglich Aussagen zur Wirkung der Nootropika zulassen, mus die Bewertung der Wirksamkeit

Effects of Nefiracetam, a Novel Pyrrolidone‐type Nootropic Agent, on the Amygdala‐kindled Seizures in Rats

The present study focused on the effects of NEF in amygdala‐kindled seizures and its potential for antiepileptic therapy.

Pharmacological and Nonpharmacological Approaches to the Treatment of Dementia

In this chapter, the medical treatment of dementia and the social and psychological interventions that may be directed against the disease are discussed.

Anticonvulsant Properties of the Novel Nootropic Agent Nefiracetam in Seizure Models of Mice and Rats

Nefiracetam is a novel pyrrolidone‐type nootropic agent, and it has been reported to possess various pharmacologic effects as well as cognition‐enhancing effects and its potential for antiepileptic therapy.

Treatment of experimental destructive lesions of the duodenum by nootropics

Clinicians have achieved more definite success than experimental workers with the use of nootropic drugs for the treatment of many diseases of the internal organs, including peptic ulcer.

Pharmacotherapy of Memory Loss in the Geriatric Patient

  • V. Galizia
  • Medicine
    Drug intelligence & clinical pharmacy
  • 1984
Memory loss is a common problem with advancing age and a prominent symptom in dementia. Categories of drugs used to reverse memory loss and enhance recall are reviewed. Positive results have been

The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by ß‐amyloid peptide

The metabolic enhancer piracetam has been shown to improve mitochondrial dysfunction following brain aging and experimentally induced oxidative stress and is implicated in the pathogenesis of Alzheimer's disease.

New Pharmacological Perspectives on Nootropic Drugs

While complete agreement between pharmacologists has not yet been attained, the vast majority agree that nootropic drugs have at least the following properties in common: they improve some aspect of cognitive performance—usually learning and/or memory in animals.

Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia

Present evidence suggests some therapeutic efficacy for nootropics and metabolically active compounds as well as alkylxanthines in the treatment of dementia.



Effect of different psychoactive drugs on serum and brain tryptophan levels.

The results obtained suggest that tryptophan may be involved to varying extents in the activity of different psychoactive compounds.

Piracetam activity may differ according to the age of the recipient mouse.

Piracetam significantly improves the learning capacity of young mice, but the drug is remarkably more active in improving the performance by old mice, suggesting that this compound is especially effective in restoring the neurobiological setting of the aging brain.

The Pharmacology of Callosal Transmission: A General Survey

The neuropharmacologist has a double task in this field: first, a fundamental one, contributing to the elucidation of the nature of interhemispheric transmission, by using drugs, and secondly, an applied one, producing drugs that either selectively enhance the efficiency of inter Hemispheric Transmission or act to compensate eventual deficits.


2‐Hydroxy‐GABA is the most potent inhibitor of GABA uptake yet described and these analogues are potential substrates for the GABA transport system and possible ‘false transmitters’.